Evidence for a sex-specific contribution of polygenic load for anorexia nervosa to body weight and prefrontal brain structure in nonclinical individuals
Publication date: December 2019 Source: Neuropsychopharmacology, Volume 44, Issue 13 Author(s): Elisabeth J. Leehr, Nils Opel, Janina Werner, Ronny Redlich, Jonathan Repple, Dominik Grotegerd, Katharina Dohm, Janik Goltermann, Joscha Böhnlein, Azmeraw T. Amare, Lisa Sindermann, Katharina Förster, Susanne Meinert, Verena Enneking, Maike Richter, Tim Hahn, Bernhard T. Baune, Udo Dannlowski
Evidence for a sex-specific contribution of polygenic load for anorexia nervosa to body weight and prefrontal brain structure in nonclinical individuals. // Neuropsychopharmacology. – URL: https://www.sciencedirect.com/science/article/pii/S0893133X2603664X?dgcid=rss_sd_all
Evidence for a sex-specific contribution of polygenic load for anorexia nervosa to body weight and prefrontal brain structure in nonclinical individuals. Neuropsychopharmacology. https://www.sciencedirect.com/science/article/pii/S0893133X2603664X?dgcid=rss_sd_all
“Evidence for a sex-specific contribution of polygenic load for anorexia nervosa to body weight and prefrontal brain structure in nonclinical individuals.” Neuropsychopharmacology.
@article{article60152,
title = {Evidence for a sex-specific contribution of polygenic load for anorexia nervosa to body weight and prefrontal brain structure in nonclinical individuals},
journal = {Neuropsychopharmacology},
url = {https://www.sciencedirect.com/science/article/pii/S0893133X2603664X?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...